Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis
ABSTRACT Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier. Methods Our retrospective study aimed to compare the efficacy and safety of vinorelbine with or without thiotepa in patients with HER2‐n...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849738265542787072 |
|---|---|
| author | Aurelia Robert Paul Gougis Elise Dumas Rebecca Loison Victoire De Castelbajac Marc Espie Sylvie Giacchetti Caroline Cuvier Lamia Hassani Johanna Wassermann Luca Campedel Marianne Veyri Aurore Vozy Jean Philippe Spano Luis Teixeira Baptiste Abbar |
| author_facet | Aurelia Robert Paul Gougis Elise Dumas Rebecca Loison Victoire De Castelbajac Marc Espie Sylvie Giacchetti Caroline Cuvier Lamia Hassani Johanna Wassermann Luca Campedel Marianne Veyri Aurore Vozy Jean Philippe Spano Luis Teixeira Baptiste Abbar |
| author_sort | Aurelia Robert |
| collection | DOAJ |
| description | ABSTRACT Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier. Methods Our retrospective study aimed to compare the efficacy and safety of vinorelbine with or without thiotepa in patients with HER2‐negative mBC. We used propensity score inverse probability of treatment weighting to ensure comparability between groups. Results Vinorelbine‐thiotepa was not significantly associated with improved median progression‐free survival (PFS) (4.9 vs. 3.0 months, p = 0.138) or median overall survival (OS) (11.8 vs. 11.9 months, p = 0.961) compared to vinorelbine. However, in the central nervous system (CNS) metastasis subgroup, vinorelbine‐thiotepa was associated with a longer median PFS (4.9 vs. 2.1 months, p = 0.013) and CNS‐PFS (6.12 vs. 2.20 months, p = 0.007). The combination was also associated with a higher rate of grade ≥ 3 adverse events (54.3% vs. 37.9%, p = 0.021). Conclusion While no overall benefit in PFS or OS was found, vinorelbine‐thiotepa may be associated with improved PFS in mBC patients with CNS metastasis. |
| format | Article |
| id | doaj-art-361d08e2f0774cb282b3d6a9b94975a4 |
| institution | DOAJ |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-361d08e2f0774cb282b3d6a9b94975a42025-08-20T03:06:40ZengWileyCancer Medicine2045-76342025-08-011415n/an/a10.1002/cam4.71102Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score AnalysisAurelia Robert0Paul Gougis1Elise Dumas2Rebecca Loison3Victoire De Castelbajac4Marc Espie5Sylvie Giacchetti6Caroline Cuvier7Lamia Hassani8Johanna Wassermann9Luca Campedel10Marianne Veyri11Aurore Vozy12Jean Philippe Spano13Luis Teixeira14Baptiste Abbar15Department of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceInstitut Curie, Residual Tumor & Response to Treatment Laboratory, RT2Lab INSERM U932 Immunity and Cancer Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceSorbonneUniversité, AP‐HP, Pitié‐SalpêtrièreHospital, Department of Pharmacy Paris FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceDepartment ofMedical and Thoracic Oncology, CHU Gabriel Montpied Clermont‐Ferrand FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceDepartment of Senology Université Paris Cité, AP‐HP, Saint‐Louis Hospital Paris FranceDepartment of Medical Oncology Sorbonne Université, Assistance Publique—Hôpitaux de Paris (AP‐HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié‐Salpêtrière Hospital Paris FranceABSTRACT Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier. Methods Our retrospective study aimed to compare the efficacy and safety of vinorelbine with or without thiotepa in patients with HER2‐negative mBC. We used propensity score inverse probability of treatment weighting to ensure comparability between groups. Results Vinorelbine‐thiotepa was not significantly associated with improved median progression‐free survival (PFS) (4.9 vs. 3.0 months, p = 0.138) or median overall survival (OS) (11.8 vs. 11.9 months, p = 0.961) compared to vinorelbine. However, in the central nervous system (CNS) metastasis subgroup, vinorelbine‐thiotepa was associated with a longer median PFS (4.9 vs. 2.1 months, p = 0.013) and CNS‐PFS (6.12 vs. 2.20 months, p = 0.007). The combination was also associated with a higher rate of grade ≥ 3 adverse events (54.3% vs. 37.9%, p = 0.021). Conclusion While no overall benefit in PFS or OS was found, vinorelbine‐thiotepa may be associated with improved PFS in mBC patients with CNS metastasis.https://doi.org/10.1002/cam4.71102breast cancerpropensity scorereal‐world evidencethiotepavinorelbine |
| spellingShingle | Aurelia Robert Paul Gougis Elise Dumas Rebecca Loison Victoire De Castelbajac Marc Espie Sylvie Giacchetti Caroline Cuvier Lamia Hassani Johanna Wassermann Luca Campedel Marianne Veyri Aurore Vozy Jean Philippe Spano Luis Teixeira Baptiste Abbar Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis Cancer Medicine breast cancer propensity score real‐world evidence thiotepa vinorelbine |
| title | Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis |
| title_full | Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis |
| title_fullStr | Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis |
| title_full_unstemmed | Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis |
| title_short | Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis |
| title_sort | vinorelbine with or without thiotepa for her2 negative metastatic breast cancer a propensity score analysis |
| topic | breast cancer propensity score real‐world evidence thiotepa vinorelbine |
| url | https://doi.org/10.1002/cam4.71102 |
| work_keys_str_mv | AT aureliarobert vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT paulgougis vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT elisedumas vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT rebeccaloison vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT victoiredecastelbajac vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT marcespie vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT sylviegiacchetti vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT carolinecuvier vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT lamiahassani vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT johannawassermann vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT lucacampedel vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT marianneveyri vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT aurorevozy vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT jeanphilippespano vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT luisteixeira vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis AT baptisteabbar vinorelbinewithorwithoutthiotepaforher2negativemetastaticbreastcancerapropensityscoreanalysis |